Literature DB >> 18609421

Inappropriate crying and laughing in Parkinson disease and movement disorders.

Mustafa S Siddiqui1, Hubert H Fernandez, Cynthia W Garvan, Lindsey Kirsch-Darrow, Dawn Bowers, Ramon L Rodriguez, Charles E Jacobson, Christian Rosado, Swetha Vaidyanathan, Kelly D Foote, Michael S Okun.   

Abstract

OBJECTIVE: To examine in a pilot study inappropriate crying and laughing (also termed pseudobulbar affect (PBA)) and underlying mood disturbances in a large clinic based population of Parkinson's disease and movement disorder patients.
BACKGROUND: PBA is characterized by uncontrollable laughter without mirth, or alternatively crying without the feeling of sadness. It is a common condition affecting more than one million people with neurological diseases. While PBA has been studied in many neurological diseases, little is known about its prevalence in movement disorders, or its relationship to more chronic mood disturbances. We carried out this pilot study to examine this relationship.
METHODS: Seven hundred and nineteen out of 860 consecutive patients who visited our Movement Disorders Center met inclusion criteria (i.e. > or = 18 years of age, formal diagnosis by a movement disorder specialist, completion of PBA questionnaire, and absence of brain surgery including deep brain stimulation). All subjects were interviewed for symptoms of PBA during their visit. In addition, 661 of these patients completed both the Visual Analog Mood Scale (VAMS) and Beck Depression Inventory I (BDI-I).
RESULTS: Thirty-seven of the 719 reported PBA symptoms; 75.7% (28/37) had pathological 'crying', 13.5% (5/37) had pathological 'laughing' and 10.8% (4/37) had both. The prevalence of PBA in individual diagnostic categories was: 4.7% (18/387) of idiopathic Parkinson's disease (PD), 2.7% (2/74) of primary dystonia, 3.1% (2/65) of essential tremor (ET), 7.8% (8/108) of patients with other forms of Parkinsonism, 21.7% (5/23) of psychogenic movement disorders, 0% (0/18) of patients with combined PD and ET, and 4.5% (2/44) of other movement disorders. Patients with PBA had a higher total BDI score (P=0.0278) and VAMS 'tiredness' score (P=0.0109). In patients on antidepressant therapy the prevalence of PBA was 7.1% compared to 2.7% in the group not on therapy (P=0.0094).
CONCLUSION: PBA was present in most movement disorders, but especially prevalent in parkinsonism. PBA patients in this cohort had more chronic depressive symptoms and tiredness.

Entities:  

Mesh:

Year:  2009        PMID: 18609421     DOI: 10.1080/15622970701639445

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  15 in total

1.  Pseudobulbar affect: prevalence and quality of life impact in movement disorders.

Authors:  Roy E Strowd; Michael S Cartwright; Michael S Okun; Ihtsham Haq; Mustafa S Siddiqui
Journal:  J Neurol       Date:  2010-04-08       Impact factor: 4.849

2.  Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.

Authors:  Kerri A Schoedel; Laura E Pope; Edward M Sellers
Journal:  Clin Drug Investig       Date:  2012-03-01       Impact factor: 2.859

3.  Pathological laughter as onset symptom in atypical parkinsonisms.

Authors:  Anna De Rosa; Sabina Pappatà; Silvio Peluso; Francesco Saccà; Maria Lieto; Alessandro Filla; Giuseppe De Michele
Journal:  J Neurol       Date:  2016-11-24       Impact factor: 4.849

Review 4.  Essential tremor--a neurodegenerative disorder associated with cognitive defects?

Authors:  Félix Bermejo-Pareja
Journal:  Nat Rev Neurol       Date:  2011-04-12       Impact factor: 42.937

5.  Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.

Authors:  Michael Fralick; Chana A Sacks; Aaron S Kesselheim
Journal:  JAMA Intern Med       Date:  2019-02-01       Impact factor: 21.873

6.  The cognitive side of essential tremor: what are the therapeutic implications?

Authors:  Sarah C Janicki; Stephanie Cosentino; Elan D Louis
Journal:  Ther Adv Neurol Disord       Date:  2013-11       Impact factor: 6.570

7.  A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers.

Authors:  Laura E Pope; Kerri A Schoedel; Cynthia Bartlett; Edward M Sellers
Journal:  Clin Drug Investig       Date:  2012-08-01       Impact factor: 2.859

8.  PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.

Authors:  Benjamin Rix Brooks; David Crumpacker; Jonathan Fellus; Daniel Kantor; Randall E Kaye
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

Review 9.  Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect.

Authors:  Kerri A Schoedel; Sarah A Morrow; Edward M Sellers
Journal:  Neuropsychiatr Dis Treat       Date:  2014-06-26       Impact factor: 2.570

Review 10.  Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.

Authors:  Erik P Pioro
Journal:  Neurol Ther       Date:  2014-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.